|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study elucidates a novel role of BMP6-induced modulation of the tumor microenvironment.
|
30171260 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, BMP-6 is a tumor suppressor in lung cancer and loss of BMP-6 expression is significantly associated with a poor prognosis in patients with NSCLC.
|
30675259 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High expression of BMP7 was found to be significantly associated with better prognosis in both estrogen receptor (ER)‑positive (ER+) (P<0.001) and ER‑negative (ER‑) tumors (P<0.001), whereas high expression of BMP6 was associated with better prognosis only in ER+ tumors (P=0.004); it was associated with worse prognosis in ER‑ tumors (P=0.006).
|
31524275 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, higher levels of CCL2 and BMP6 were more commonly observed in intra-femoral transplanted tumours as compared to subcutaneous-transplanted tumours in the patient-derived PCSD1 bone-niche model.
|
29381686 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations suggest a novel role of BMP-6 in the inhibition of breast cancer metastasis by regulating secretion of MMPs in the tumor microenvironment.
|
26751737 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone morphogenetic protein 6 (BMP6) is an important regulator of cell growth, differentiation and apoptosis in various types of tumor.
|
24890613 |
2014 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
CpG island methylation of BMP6 is found in high frequency in CRC and this epigenetic event is associated with suppressed protein expression in the tumor tissue.
|
25227796 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although bone morphogenetic protein-6 (BMP-6) has been identified as a tumor suppressor associated with breast cancer differentiation and metastasis, the potential roles of BMP-6 in regulating cell cycle progression have not been fully examined.
|
24012720 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
|
23710822 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages.
|
23633487 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Instead, a high level of inhibitor of differentiation 1, a downstream factor of BMP6, was associated with shorter survival in patients whose tumors stained strongly for BMP6.
|
22364398 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations suggest a novel role of BMP-6/HO-1 cascade to relieve breast cancer metastasis by regulating the secretion of growth factors in tumor microenvironment.
|
21136273 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BMP-6, as a member of TGF-β superfamily, is closely correlated with tumor differentiation and skeletal metastasis.
|
20401668 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone morphogenetic protein-6 (BMP-6) is closely correlated with tumor differentiation and skeletal metastasis.
|
17574840 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies indicate that BMP-6 is closely related to tumor differentiation and metastasis.
|
17997862 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone morphogenetic protein-6 (BMP-6) is closely correlated with tumor differentiation and skeletal metastasis.
|
16232348 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to examine the expression and regulation of BMP-6 in esophageal carcinoma and to determine the relationship of its expression with tumor characteristics and survival.
|
10449605 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BMP-6 mRNA and protein expression, however, was higher in prostate cancer as compared with adjacent normal prostate, with higher-grade tumors (Gleason score of 6 or more) having greater BMP-6 immunostaining than the lower-grade tumors (Gleason score of 4 or less).
|
9116752 |
1995 |